GET DAILY SIGNALSPurple Biotech (PPBT): The -11% Slide Over 30 Days and Key Factors Ahead
Key Takeaways
- Purple Biotech (PPBT) shares declined roughly 11% over the trailing 30 days, moving from about $1.46 to $1.30.
- The pullback was driven by financing and dilution concerns tied to a low cash position and recent shelf-registration filings, which weighed on the micro-cap name.
- Mid-October marked the weakest stretch of the period, with shares touching a 52-week intraday low near $0.91 before recovering more than 35% into early November.
- Momentum returned late in the period after the company announced its IM1240 abstract was selected for an oral presentation at the EORTC-NCI-AACR Symposium.
- Over the last quarter the stock is down about 10% but has been highly volatile, spiking on a U.S. patent allowance before giving back the gains.
- More detail on valuation and upcoming catalysts is available on the Price Targets, Earnings, and Forecast pages.
- Investors can also explore Trending AI Robots for curated, top-performing AI trading bots.
Purple Biotech (PPBT) Company Snapshot
Purple Biotech Ltd (PPBT) is a clinical-stage oncology company headquartered in Rehovot, Israel, focused on therapies designed to overcome tumor immune evasion and drug resistance. Its pipeline centers on CM24, a humanized monoclonal antibody targeting CEACAM1 that is being evaluated in a Phase 2 study in pancreatic ductal adenocarcinoma in combination with the PD-1 inhibitor nivolumab under a collaboration with Bristol Myers Squibb; NT219, a small molecule targeting IRS1/2 and STAT3 in Phase 2 development for head and neck squamous cell carcinoma and colorectal adenocarcinoma; and the CAPTN-3 platform, a preclinical class of multispecific antibodies led by IM1240 and IM1305. As a pre-revenue clinical-stage company, PPBT generates no product sales, so investors follow it primarily for clinical data readouts, regulatory milestones, and its ability to fund operations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PPBT Stock Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, PPBT fell about 11%, from a closing level near $1.46 to $1.30. The path was not linear: shares slid through much of October, reaching a 52-week intraday low near $0.91 in late October, before rebounding into early November. The stock closed at $1.30 on November 6, 2026, up 6.6% in the latest session. The three-month picture is similar in magnitude but more volatile: from roughly $1.44 in early August, shares are down about 10%, though they briefly traded as high as $2.59 intraday in early September after a U.S. patent allowance before fading back. From what I see, the volatility underscores the challenges of tracking micro-cap biotechs.
What Drove the Recent Price Action
The dominant theme was balance-sheet pressure. With a modest cash position — reported total cash of roughly $6.1 million in the most recent quarter — and no product revenue, Purple Biotech has relied on equity financing, and recent shelf-registration filings, including a $200 million mixed-shelf prospectus and subsequent F-3/A amendments, renewed concerns about potential dilution. That overhang, combined with the thin trading liquidity typical of micro-cap biotechs, contributed to the October slide. The September patent-allowance rally also continued to unwind early in the period. Sentiment shifted late in October, however, when the company announced that its IM1240 abstract was selected for an oral presentation at the EORTC-NCI-AACR Symposium, a milestone that helped fuel the recovery into early November. I’m watching this closely as a potential sentiment catalyst.
Quarterly Drivers and Offsetting Influences
The broader three-month trend has been shaped by clinical and regulatory progress set against financing risk. In early September, shares spiked after the U.S. Patent and Trademark Office issued a notice of allowance for a patent covering Purple Biotech's tri-specific antibody constructs and methods, strengthening intellectual-property protection around the CAPTN-3 platform. Earlier in the quarter, H.C. Wainwright lowered its price target to $17 from $30 while maintaining a Buy rating, citing the company's low cash position. Those offsetting forces — pipeline progress on one side and funding uncertainty on the other — produced the quarter's wide trading range and overall modest decline.
Key Catalysts on the Horizon
Investors will be watching the company's presentation of IM1240 data at the EORTC-NCI-AACR Symposium, scheduled for November 20, 2026, along with upcoming quarterly results expected in November. The key structural question remains the balance sheet: how Purple Biotech finances its pipeline with limited cash will influence sentiment and any future dilution. Clinical updates for CM24 in pancreatic cancer and NT219 in head and neck and colorectal indications, plus further CAPTN-3 preclinical data, are additional catalysts. Macro factors such as broader risk appetite for speculative biotech names also matter. Clinical-stage investing carries substantial risk, and none of this constitutes investment advice. One thing that stands out is how these near-term events could shape the next move.
Using Tickeron AI Tools for Deeper Analysis
In my own research process, I frequently reference Tickeron’s AI Trend Prediction Engine to gauge momentum patterns in names like this one before making allocation decisions. It helps surface comparable signals across the sector without replacing fundamental review. The platform also lets me cross-check volatility metrics against historical ranges, which adds another layer to the picture. Overall, these tools support a more structured approach to monitoring clinical-stage equities amid financing noise.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT's Stochastic Oscillator sits in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PPBT's RSI Indicator exited the oversold zone, 45 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
Advertisement